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Background: Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated
the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. This global, randomized, phase III study
investigated the efficacy and safety of nintedanib in patients with refractory CRC after failure of standard therapies.
Patients and methods: Eligible patients (Eastern Cooperative Oncology Group performance status 0–1, with histologically/
cytologically confirmed metastatic/locally advanced CRC adenocarcinoma unamenable to surgery and/or radiotherapy) were
randomized 1 : 1 to receive nintedanib (200 mg twice daily) or placebo (twice daily), until disease progression or undue toxicity.
Patients were stratified by previous regorafenib, time from onset of metastatic disease to randomization, and region. Co-primary
end points were overall survival (OS) and progression-free survival (PFS) by central review. Secondary end points included
objective tumor response and disease control by central review.
Results: From October 2014 to January 2016, 768 patients were randomized; 765 were treated (nintedanib n¼ 384; placebo
n¼ 381). Median follow-up was 13.4 months (interquartile range 11.1–15.7). OS was not improved [median OS 6.4 months with
nintedanib versus 6.0 months with placebo; hazard ratio (HR), 1.01; 95% confidence interval (CI), 0.86–1.19; P¼ 0.8659]. There
was a significant but modest increase in PFS with nintedanib versus placebo (median PFS 1.5 versus 1.4 months, respectively; HR
0.58; 95% CI 0.49–0.69; P< 0.0001). There were no complete or partial responses. Adverse events (AEs) occurred in 97% of 384
nintedanib-treated patients and 93% of 381 placebo-treated patients. The most frequent grade3 AEs were liver-related AEs
(nintedanib 16%; placebo 8%) and fatigue (nintedanib 9%; placebo 6%).
Conclusions: The study failed to meet both co-primary end points. Nintedanib did not improve OS and was associated with a
significant but modest increase in PFS versus placebo. Nintedanib was well tolerated.
VC The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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Introduction
While combination cytotoxic therapy remains the backbone of
treatment in metastatic colorectal cancer (CRC), inhibition of
angiogenesis via the vascular endothelial growth factor (VEGF)
pathway is now also a well-established treatment approach in
CRC. A number of angiogenesis-targeting agents are approved,
either in combination with fluoropyrimidine-based chemotherapy
in first- or second-line (bevacizumab, aflibercept, ramucirumab),
or as monotherapy in the last-line setting (regorafenib) [1, 2].
Owing to these advances, patients with metastatic CRC typically
achieve an overall survival (OS) of30 months [1].
Regorafenib and trifluridine/tipiracil (TAS-102) have both
been shown to improve survival compared with best supportive
care (BSC) in patients who had previously received all available
standard therapies; they are approved for use in refractory CRC
[3, 4]. However, both agents are associated with adverse events
(AEs) that may be dose limiting [4, 5]. As such, there remains a
need for active and better-tolerated treatments that prolong sur-
vival while maintaining patient quality of life (QoL).
Nintedanib is an oral, twice-daily, triple angiokinase inhibitor
of VEGF receptors 1–3, platelet-derived growth factor receptor-
a/b, and fibroblast growth factor receptors 1–3, which also inhib-
its the kinases RET, FLT3, Lck and Lyn [6, 7], and has been shown
to delay or arrest tumor growth in xenograft models of solid
tumors [6]. In the clinic, nintedanib monotherapy has been
shown to exert an antiangiogenic effect in 67% of patients with
advanced, refractory CRC in a phase I study, while stabilizing dis-
ease and maintaining a manageable safety profile [7]. On the basis
of these results, the manageable tolerability profile expected with
nintedanib [8], and the unmet need in this patient population,
we hypothesized that nintedanib would be a suitable treatment of
patients with CRC who had failed all currently approved thera-
pies but could benefit from additional treatment. Here, we pre-
sent the results of the phase III LUME-Colon 1 study that
assessed the efficacy and safety of nintedanib in patients with re-
fractory CRC after failure of standard therapies.
Patients and methods
Study design and participants
LUME-Colon 1 was a randomized, double-blind, placebo-controlled, global,
phase III trial. Eligible patients had histologically or cytologically confirmed
metastatic or locally advanced colorectal adenocarcinoma not amenable to
curative surgery and/or radiotherapy. Patients were required to have pro-
gressed on approved standard therapies or have experienced unacceptable tox-
icity. Full inclusion and exclusion criteria have been reported previously [9],
and are shown in the protocol (supplementary appendix, available at Annals of
Oncology online). Previous treatment with regorafenib and trifluridine/tipiracil
was permitted; however, the proportion of regorafenib-naı̈ve patients was lim-
ited (maximum 70%).
The protocol was approved by health authorities and independent eth-
ics committees or institutional review boards based on local regulations.




382 allocated to placebo
(n = 381 treated; n = 1 not treated)
386 allocated to nintedanib







379 patients discontinued treatment
• RECIST PD (n = 324)
• AE due to worsening of cancer
  (n = 31)
• Other AE (n = 8)
• Patient refusal, other, etc. (n = 16)
381 patients discontinued treatment
• RECIST PD (n = 318)
• AE due to worsening of cancer
  (n = 32)
• Other AE (n = 18)
• Patient refusal, other, etc. (n = 13)
Figure 1. Patient disposition. Three patients were randomized but not treated in the study, two patients (placebo n ¼1; nintedanib n¼1)
due to worsening of underlying disease and one (nintedanib) due to noncompliance with the study protocol. AE, adverse event; PD, progres-
sive disease; RECIST, Response Evaluation Criteria in Solid Tumors.
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LUME-Colon 1 followed the guiding principles of the Declaration of
Helsinki and was conducted in accordance with good clinical practice as
well as local laws and regulations. All patients provided written informed
consent. The database cut-off date for these analyses was 14 June 2016.
Patients were randomized 1 : 1 to receive oral nintedanib 200 mg twice
daily plus BSC or matching placebo twice daily plus BSC in 21-day
courses until disease progression, undue toxicity, or withdrawal of
consent. Randomization was stratified by previous treatment with
regorafenib (yes versus no), time from the onset of metastatic disease
until randomization in the trial (<24 versus 24 months), and geo-
graphical region (Western Europe, North America and Australia; Asia;
and rest of the world). Predefined dose reductions were permitted to
manage AEs (supplementary appendix, available at Annals of Oncology
online). Patients were followed up every 3 weeks during treatment; tumor
Table 1. Baseline characteristics and previous treatments
Nintedanib (n 5 386) Placebo (n 5 382)
Median age, years (range) 62 (22–85) 62 (23–83)
Sex (%)
Male 236 (61.1) 218 (57.1)
Racea (%)
Caucasian 279 (72.3) 268 (70.2)
Asian 97 (25.1) 104 (27.2)
Other 5 (1.3) 3 (0.8)
Missing 5 (1.3) 9 (2.4)
ECOG PS at baselineb (%)
0 162 (42.0) 142 (37.2)
1 223 (57.8) 240 (62.8)
Region (%)
Western Europe, North America, Australia 231 (59.8) 227 (59.4)
Asia 95 (24.6) 98 (25.7)
Other 60 (15.5) 57 (14.9)
Time from onset of metastatic disease until randomization (%)
<24 months 108 (28.0) 110 (28.8)
24 months 278 (72.0) 272 (71.2)
Primary site of diseasec (%)
Colon 256 (66.3) 227 (59.4)
Rectum 130 (33.7) 154 (40.3)
Unknown 0 1 (0.3)
>1 metastatic site at screening (%) 345 (89.4) 319 (83.5)
Presence of liver metastases (%)
Yes 277 (71.8) 266 (69.6)
No 109 (28.2) 116 (30.4)
Previous treatments
Mean (SD) number of lines of previous systemic anticancer therapies (%) 3.9 (1.8) 3.9 (1.8)
3 lines of previous systemic anticancer therapies (%) 297 (76.9) 296 (77.5)
Previous systemic anticancer therapies (%)
Oxaliplatin 386 (100.0) 382 (100.0)
Fluoropyrimidine 386 (100.0) 382 (100.0)
Irinotecan 386 (100.0) 382 (100.0)
Bevacizumab or aflibercept 382 (99.0) 381 (99.7)
Bevacizumab 368 (95.3) 370 (96.9)
Aflibercept 48 (12.4) 47 (12.3)
Regorafenib 141 (36.5) 144 (37.7)
Trifluridine/tipiracil 55 (14.2) 53 (13.9)
Previous radiotherapy (%) 104 (26.9) 132 (34.6)
KRAS wild-type and other RAS wild-type patients only Nintedanib (n¼ 158) Placebo (n¼ 176)
Prior cetuximab or panitumumab (%) 158 (100.0) 175 (99.4)
Data are n (%) unless otherwise specified.
aOne patient indicated the races American Indian or Alaska Native, Black or African American and White.
bOne patient in the nintedanib arm had an ECOG PS >1.
cOne patient in the placebo arm had primary site ‘Other/unknown’.
ECOG PS, Eastern Cooperative Oncology Group performance status; SD, standard deviation.
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response was assessed by computed tomography/magnetic resonance imag-
ing every 6 weeks using Response Evaluation Criteria in Solid Tumors v1.1.
Outcomes
Co-primary end points were OS and progression-free survival (PFS) by
central review. Secondary end points were objective tumor response and
disease control by central review, and PFS by investigator assessment.
Health-related QoL (HRQoL) was evaluated and results will be published
in detail separately. Safety was assessed according to the US National
Cancer Institute Common Terminology Criteria for Adverse Events, ver-
sion 3.0.
Statistical analysis
Full details of the statistical analysis are provided in the protocol (supple-
mentary appendix, available at Annals of Oncology online). Co-primary
end points and additional efficacy outcomes were analyzed on an
intention-to-treat basis. A stratified log-rank test was used for primary ef-
ficacy analysis of both co-primary end points at a two-sided 5% level of
significance in all randomized patients. Assuming a median OS of
5 months in the control group [3], recruitment of about 50 patients per
month, and 20% loss to follow-up, 764 patients were to be randomized;
611 OS events were needed for the primary OS analysis to detect a hazard
ratio (HR) of 0.77 (median OS difference of 1.5 months) with 90%
power. It was assumed that nintedanib would increase median PFS by 2.7
weeks to 10.7 weeks versus 8 weeks with placebo (HR 0.75). As co-
primary end points, it was planned to analyze OS and PFS at the same
time once the required number of OS events had been reached. As
expected, there were more PFS than OS events, and therefore no formal
power calculation for PFS was done and as many PFS events as possible
were included in the analysis. At the time of the OS analyses, it was esti-
mated that 595 analyzable PFS events would have occurred, which would
yield a power of 95% for the PFS analysis.
HRQoL analyses were not adjusted for multiple testing. Safety data
were analyzed descriptively in all treated patients.
Results
Patient disposition is shown in Figure 1. Between 14 October
2014 and 18 January 2016, 768 patients were randomized to re-
ceive treatment with nintedanib (n¼ 386) or placebo (n¼ 382);
these comprised the efficacy population. The safety population
comprised 765 treated patients (nintedanib, n¼ 384; placebo,
n¼ 381). Most baseline characteristics were well balanced be-
tween arms, with some slight differences in primary disease site,
previous radiotherapy and number of metastatic sites between
treatment groups (Table 1).
Median treatment duration was 2.1 [interquartile range (IQR),
1.4–3.3] months in the nintedanib group and 1.4 (IQR, 1.3–2.1)
months in the placebo group. Patients treated with nintedanib
received 93.0% of the planned dose during the study, compared
with 98.4% in the placebo group. Dose reductions were required
in 19% of nintedanib-treated patients (58 required one and 14
required two dose reductions) and 3% of placebo-treated
patients (12 single dose reductions). The most common reasons
for nintedanib dose reduction were increased alanine amino-
transferase (ALT) levels, increased aspartate aminotransferase
(AST) levels and diarrhea. Dose reductions were required owing
to AEs, except in one patient receiving placebo. Treatment inter-
ruption of >14 days was required in 12 nintedanib-treated
patients (3%) and one placebo-treated patient (0.3%). Systemic
therapy after progression is shown in supplementary Table S1,
available at Annals of Oncology online (supplementary appendix,
available at Annals of Oncology online).
At the analysis of the co-primary end points of OS and PFS,
613 OS events and 687 PFS events had occurred and median
follow-up was 13.4 months (IQR, 11.1–15.7). Median OS was
6.4 months with nintedanib and 6.0 months with placebo [HR
1.01; 95% confidence interval (CI) 0.86–1.19; P¼ 0.8659; Figure
2A]. Median PFS was 1.5 versus 1.4 months (HR 0.58; 95% CI
0.49–0.69; P< 0.0001) (Figure 3A). Although not a co-primary
end point, median PFS by investigator review was 2.6 months
(95% CI 2.0–2.7) with nintedanib versus 1.4 months (95% CI
1.4–1.4) with placebo (HR 0.57; 95% CI 0.49–0.67; P< 0.0001;
supplementary Figure S1, available at Annals of Oncology online).
Analysis of OS by treatment arm and prespecified subgroup
showed that baseline number of metastatic sites (1 versus >1),
rectum as site of primary tumor (yes versus no) and Eastern
Cooperative Oncology Group performance status (0 versus 1)
all had interaction P values 0.1 (Figure 2B). The effect of




























4 6 8 10 12 14 16 18 20
Nintedanib Placebo
(n = 386) (n = 382)
Median, months 6.4 6.0
(95% Cl) (5.98–7.10) (5.22– 6.97)
HR (95% Cl)  1.01 (0.86 –1.19);
 P = 0.8659
Patients at risk
Nintedanib 386 365 283 207 143 95 49 24 13 1 0
Placebo 382 337 247 184 135 96 58 29 7 0
A
Figure 2. Overall survival. (A) Kaplan–Meier curves for intention-to-treat population. (B) Subgroup analyses (forest plot). CI, confidence inter-
val; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival. *Exploratory analysis.
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analyses (Figure 3B). Exploratory analysis of OS and PFS by pri-
mary tumor location (left versus right) showed no treatment
interaction (Figures 2B and 3B).
There were no complete or partial responses. The disease con-
trol rate was 26% in the nintedanib arm and 11% in the placebo
arm (odds ratio, 3.0; 95% CI 2.0–4.5; P< 0.0001). Median dur-
ation of disease control was 4.0 months (IQR, 2.8–4.5) with nin-
tedanib and 4.1 months (IQR, 3.0–9.6) with placebo.
Mean treatment difference (nintedanib versus placebo) was
2.66 (95% CI 0.97–4.34) for physical functioning and 1.6 (95%
CI0.04–3.27) for global health status/QoL.
The majority of patients in both treatment groups experienced
an AE (Table 2). AEs were considered treatment related in 291
patients (76%) treated with nintedanib and 195 patients (51%)
treated with placebo. The most frequent grade3 AEs in the nin-
tedanib group were liver-related AEs, mainly increased ALT (8%)
and AST (8%) levels, and fatigue.
Serious AEs were reported in 149 patients treated with ninted-
anib (39%) and 133 patients treated with placebo (35%). Of the
106 deaths due to serious AEs during the study [nintedanib n¼ 55
(14%); placebo n¼ 51 (13%)], most (n¼ 94) were the result of
progressive disease or an AE of underlying cancer [nintedanib,
n¼ 47 (12%); placebo, n¼ 47 (12%)]. Seven deaths were due to
AEs that were not associated with disease progression [nintedanib,
n¼ 6 (1.6%); placebo, n¼ 1 (0.3%)]. For two patients in the
nintedanib group and three in the placebo group, it was unknown
whether death was related to underlying disease. One patient in the
nintedanib group died of treatment-related hepatic failure, and
two patients in the placebo group died due to a treatment-related
AE.
AEs leading to treatment discontinuation were experienced
by 55 patients treated with nintedanib (14%) and 40 patients
treated with placebo (11%). The most common of these in the
nintedanib group was fatigue (n¼ 8), followed by asthenia,
decreased appetite, and malignant neoplasm progression (all
n¼ 6); in the placebo group, the most common were increased
blood bilirubin and increased AST levels (both n¼ 5).
Discussion
This study of nintedanib versus placebo in patients with refrac-
tory metastatic CRC did not meet the co-primary end point;
there was no improvement in OS, and there was a statistically sig-
nificant, but modest, improvement in PFS.
In our study, median OS was longer in the placebo arm than
was reported in the CORRECT study with regorafenib [3] and
the RECOURSE study with trifluridine/tipiracil [4]. This may
be related to more treatment options, including regorafenib and
trifluridine/tipiracil, being available post-study compared with
the CORRECT/RECOURSE studies. Exploratory post hoc analy-
ses of OS were conducted that censored patients at the start of
subsequent therapy. In this analysis, median OS was 6.1 months
(95% CI 5.6–6.6) with nintedanib compared with 5.1 months
(95% CI 4.5–5.9) with placebo (HR 0.79; 95% CI 0.65–0.96)
(supplementary Figure S2, available at Annals of Oncology
online).
Improvements in PFS were modest. However, the shape of the
PFS curves in this study, with a noticeable early drop-off in the
control arm but a later drop-off in the investigational arm, is
similar to the shape of the PFS curves in the CORRECT study [3].
A possible interpretation of these PFS data is that there is a sub-
group of patients that did benefit from nintedanib treatment.
However, this remains speculative at this stage; as shown in
Figure 3B, the effect of nintedanib on PFS was consistent in most
subgroups. Exploratory biomarker analyses are ongoing to try
and identify a biologically driven subgroup that has a more pro-
nounced benefit from nintedanib treatment. However, these
analyses will be hypothesis generating only and further investiga-
tion of nintedanib in an unselected patient population is not war-
ranted at this time.
Although there were no complete or partial responses, there
was a significant improvement in disease control with nintedanib
versus placebo due to patients achieving stable disease. Patient-
reported outcomes confirmed that overall HRQoL was not






































4 6 8 10 12 14 16 18 20
Nintedanib Placebo
(n=386) (n=382)
Median, months 1.5 1.4
(95% Cl) (1.45–2.17) (1.38–1.41)
HR (95% Cl)  0.58 (0.49–0.69);
 P<0.0001
Patients at risk
Nintedanib 386 162 51 6 5 2 1 1 1 0
Placebo 382 63 15 6 3 1 0
Figure 3. PFS by central review. (A) Kaplan–Meier curves for intention-to-treat population. (B) Subgroup analyses (forest plot). CI, confidence
interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; PFS, progression-free survival. *Exploratory
analysis.
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The safety profile of nintedanib in this study was consistent
with that previously reported in early-phase studies in patients
with CRC [7, 10], and also consistent with previously reported
studies in other cancer types [11–14]. The most frequent AEs of
grade 3 or higher were liver-related AEs, mainly increased ALT
and AST levels, and fatigue. Liver enzyme elevations were man-
ageable with dose reduction and were not a frequent reason for
treatment discontinuation. As expected, based on the mechanism
of action of nintedanib, skin-related AEs that are commonly
reported with regorafenib were not reported in the LUME-Colon 1
study.
Concerns have previously been raised regarding the feasibility
of conducting controlled trials in CRC with BSC as the compara-
tor. This trial recruited patients faster than anticipated, highlight-
ing the need for active treatment options in this setting despite
the availability of regorafenib and trifluridine/tipiracil.
Nonetheless, in this last-line treatment setting, it is especially im-
portant to consider aspects of the study design that affect
patients, such as frequency of assessments requiring clinic visits.
In summary, LUME-Colon 1 did not meet both co-primary
end points. Results demonstrated that nintedanib did not im-
prove OS and provided a statistically significant but modest in-
crease in PFS in heavily pretreated patients with metastatic CRC
that was refractory to all currently approved standard therapies.
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Table 2. AEs (safety population)
Nintedanib (n 5 384) Placebo (n 5 381)
Any grade Grade 3 Any grade Grade 3
Any AE 362 (94.3) 161 (41.9) 323 (84.8) 109 (28.6)
Fatigue 183 (47.7) 33 (8.6) 143 (37.5) 23 (6.0)
Diarrhea 175 (45.6) 10 (2.6) 59 (15.5) 2 (0.5)
Nausea 165 (43.0) 8 (2.1) 105 (27.6) 5 (1.3)
Vomiting 151 (39.3) 5 (1.3) 72 (18.9) 2 (0.5)
Liver-related 141 (36.7) 63 (16.4) 89 (23.4) 32 (8.4)
Increased ALT 96 (25.0) 31 (8.1) 27 (7.1) 7 (1.8)
Increased AST 96 (25.0) 30 (7.8) 50 (13.1) 15 (3.9)
Abdominal pain 95 (24.7) 11 (2.9) 89 (23.4) 5 (1.3)
Infection 82 (21.4) 23 (6.0) 57 (15.0) 12 (3.1)
Hyperbilirubinemia 42 (10.9) 12 (3.1) 31 (8.1) 15 (3.9)
Hypertension 42 (10.9) 18 (4.7) 17 (4.5) 3 (0.8)
Bleeding 37 (9.6) 1 (0.3) 38 (10.0) 6 (1.6)
Proteinuria 35 (9.1) 2 (0.5) 12 (3.1) 2 (0.5)
Mucositis 34 (8.9) 0 18 (4.7) 0
Electrolyte imbalance 33 (8.6) 10 (2.6) 26 (6.8) 13 (3.4)
Rash 32 (8.3) 1 (0.3) 28 (7.3) 0
Peripheral neuropathies 31 (8.1) 6 (1.6) 39 (10.2) 9 (2.4)
Cardiac failure 29 (7.6) 3 (0.8) 37 (9.7) 0
Increased ALKP 28 (7.3) 7 (1.8) 22 (5.8) 8 (2.1)
Anemia 28 (7.3) 8 (2.1) 30 (7.9) 13 (3.4)
Cholestasis and jaundice of hepatic origin 21 (5.5) 9 (2.3) 15 (3.9) 7 (1.8)
Hepatic failure 16 (4.2) 12 (3.1) 18 (4.7) 10 (2.6)
Renal failure 12 (3.1) 9 (2.3) 6 (1.6) 2 (0.5)
Increased GGT 10 (2.6) 9 (2.3) 3 (0.8) 2 (0.5)
AEs shown by user-defined category using US National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. User-defined AE
categories represent groupings of AEs by medical concept, e.g. Standardized MedDRA Queries or tailored searches. User-defined categories for nintedanib
include identified adverse drug reactions and potential risks of nintedanib, of other VEGF(R) inhibitors, of chemotherapies and of other agents used in this
setting, as well as conditions of interest in the treated patient population.
AE, adverse event; ALKP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; VEGF(R),
vascular endothelial growth factor (receptor).
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